Who is sponsoring NCT05861557?

NCT05861557 is sponsored by Tianjin Medical University General Hospital.

What drugs are being tested in NCT05861557?

Interventions in NCT05861557: Toripalimab, Stereotactic Body Radiation Therapy (SBRT).

What condition does NCT05861557 study?

NCT05861557 studies Locally Advanced Head and Neck Squamous Cell Carcinoma.

Is NCT05861557 still recruiting?

NCT05861557 is currently status unknown. Last updated 17 May 2023.

Last reviewed 2023-05-17 · How we verify

NCT05861557

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Neoadjuvant Radiotherapy Combined With Toripalimab for Locally Advanced Head and Neck Squamous Cell Carcinoma

Status unknown Phase 2 Last updated 17 May 2023

What this trial tests

Phase 2 trial testing Toripalimab in Locally Advanced Head and Neck Squamous Cell Carcinoma in 23 participants. Status unknown.

Timeline

20 May 2023

Primary endpoint
20 May 2024

20 May 2025

Quick facts

Lead sponsor	Tianjin Medical University General Hospital
Phase	Phase 2
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	23
Start date	20 May 2023
Primary completion	20 May 2024
Estimated completion	20 May 2025
Sites	2 locations across China

Drugs / interventions tested

Toripalimab (TORIPALIMAB) — full drug profile →
Stereotactic Body Radiation Therapy (SBRT) — full drug profile →

Conditions studied

Locally Advanced Head and Neck Squamous Cell Carcinoma — all drugs for Locally Advanced Head and Neck Squamous Cell Carcinoma →

Sponsor

Tianjin Medical University General Hospital

Who can join

18 and older, any sex, with Locally Advanced Head and Neck Squamous Cell Carcinoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a phase II study. Twenty-three patients with locally advanced head and neck squamous cell carcinoma were planned to be enrolled to assess the efficacy and safety of neoadjuvant immunotherapy combined with radiotherapy.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Immunotherapy during the Immediate Perioperative Period: A Promising Approach against Metastatic Disease.
Sandbank E, Eckerling A, Margalit A, Sorski L, et al · · 2023 · cited 10× · PMID 37623021 · DOI 10.3390/curroncol30080540
[Application of neoadjuvant immunotherapy in head and neck squamous cell carcinoma: From mechanisms to clinical practice].
Chen J, Zhang J, Kuang Y, Chen Y, et al · · 2025 · PMID 42032983 · DOI 10.11817/j.issn.1672-7347.2025.250271

Verify or expand the search:

Other trials of Toripalimab

Trials testing the same drug.

NCT07371897 — Toripalimab ± Chemo as Neoadjuvant Therapy in LA-HNSCC: A Phase III Trial · Phase 3 · not yet recruiting
NCT07423078 — Window of Opportunity in Preserving Laryngeal Function Trial · Phase 2 · recruiting
NCT07480733 — Phase II Study of JS212/JS213 as Monotherapy and in Combination in Patients With Advanced Malignant Solid Tumors · Phase 2 · not yet recruiting
NCT07320963 — Chidamide in Combination With Toripalimab and Anlotinib in Recurrent/Metastatic Nasopharyngeal Carcinoma. · Phase 1, PHASE2 · not yet recruiting
NCT07469956 — Surufatinib Plus mFOLFIRINOX and PD-1 Inhibitor as the Neoadjuvant Therapy for High-risk or Borderline Resectable Pancre · Phase 2 · not yet recruiting

Other recruiting trials for Locally Advanced Head and Neck Squamous Cell Carcinoma

Currently open trials in the same condition.

NCT07524452 — Becotatug Vedotin (MRG003) in Combination With PD-1 Inhibitor Versus PD-1 Inhibitor for the Treatment of EGFR-positive, · Phase 3 · recruiting
NCT07369882 — Comparison of Efficacy Between De-escalated Surgery and Standard Surgery After Neoadjuvant Immunotherapy in Locally Adva · NA · recruiting
NCT07371234 — Low-Dose Radiotherapy and Anti-PD-1 Immunotherapy as Neoadjuvant Treatment for Resectable Locally Advanced Head and Neck · Phase 2 · recruiting
NCT06470217 — Tirilizumab with Albumin-bound Paclitaxel and Cisplatin for Locally Advanced Resectable Oral Squamous Cell Carcinoma · Phase 2 · recruiting
NCT06240689 — A Prospective Randomized Controlled Study of Immune Checkpoint Maintenance Therapy After Radiotherapy and Chemotherapy f · Phase 2 · recruiting

Other Tianjin Medical University General Hospital trials

Trials by the same sponsor.

NCT06228781 — Autologous Hematopoietic Stem Cell Transplantation for Refractory Multiple Sclerosis · NA · not yet recruiting
NCT07498595 — TILs Plus Third-Generation EGFR-TKI Therapy for TKI-Resistant NSCLC · EARLY_PHASE1 · not yet recruiting
NCT07498439 — TILs Therapy for Multiple Primary Early-Stage NSCLC · EARLY_PHASE1 · not yet recruiting
NCT07018375 — The Effect of Oliceridine Patient-Controlled Intravenous Analgesia on Postoperative Chronic Pain After Video-Assisted Th · Phase 4 · not yet recruiting
NCT07420296 — Modified Zipper Therapy for AQP4-IgG Positive Neuromyelitis Optica Spectrum Disorder · Phase 3 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05861557 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Tianjin Medical University General Hospital
Last refreshed: 17 May 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05861557.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing